A molecular test returned a positive result for Elizabethkingia anophelis with 99% sequence identity but no quantitative copy-number signal; what does this indicate and how should the patient be managed?

Elizabethkingia anophelis “positive” on MicroGenDX with 99% identity but zero copies: interpretation and management

Bold recommendation: Treat this as a likely false-positive/trace contamination or non-clinically significant detection; do not start targeted anti-Elizabethkingia therapy unless you have corroborating clinical evidence (compatible syndrome) plus confirmatory culture or quantitative molecular signal from a sterile site. 1, 2

How to interpret “99% identity, 0 copies”

• 99% sequence identity with no quantitative copy number (i.e., at/below limit of blank/quantification) is an equivocal molecular hit that should not be actioned as a true infection per reporting standards for nucleic-acid assays; such low-level calls require confirmation or repeat testing before being considered clinically real 2.
• IDSA/ASM lab guidance: NAATs are excellent for detection but can detect residual/irrelevant DNA; results must be interpreted with specimen source, quantity, and clinical syndrome; DNA detection alone should not be used to monitor or guide therapy without supportive evidence 1.

Clinical implications for morbidity, mortality, QoL

• True Elizabethkingia anophelis infections (bacteremia, pneumonia, meningitis, neonatal sepsis) can be severe and multidrug resistant with high mortality; missing a real case is dangerous—but overtreating on a likely artifactual result exposes patients to toxic, prolonged antibiotics without benefit 3, 4, 5, 6.
• Therefore, the safest approach for patient outcomes is confirm before committing to therapy.

Action algorithm

1. Assess clinical syndrome and specimen relevance

   • If the report is from a non-sterile site (e.g., sputum, BAL, wound, urine without symptoms) and patient lacks a compatible invasive syndrome (sepsis, meningitis, progressive pneumonia, device-related infection): classify as low-likelihood; proceed to Step 2 without antibiotics targeted to Elizabethkingia 1.
   • If patient has a compatible severe syndrome (e.g., persistent bacteremia, meningitis signs, ventilator-associated pneumonia) or the original specimen is a sterile site (blood/CSF): elevate suspicion and proceed urgently to Step 2 and Step 3.

2. Confirm or refute the signal

   • Repeat/orthogonal testing:
     • Obtain two sets of blood cultures (and CSF culture if meningitis suspected); hold extended if needed; request lab speciation methods able to distinguish E. anophelis from E. meningoseptica (MALDI-TOF with updated library or mNGS) 7, 1.
     • Repeat molecular test with quantitative metrics; if below the laboratory’s limit of blank/quantification, treat as not detected per expert consensus; if between LOB and LOD, require repeat/orthogonal confirmation before acting 2.
   • Ensure proper specimen collection/transport to reduce contamination and false calls 1.

3. Decide therapy based on confirmation and severity

   • If cultures and repeat/quantitative NAAT are negative and the patient is clinically stable: do not treat for Elizabethkingia; search for alternative diagnoses 1, 2.
   • If confirmed E. anophelis from a sterile site or there is compelling quantitative molecular evidence with compatible severe illness:
     • Start directed therapy promptly due to high mortality risk; avoid beta-lactams/carbapenems/aminoglycosides given intrinsic resistance; options with clinical and experimental support include:
       • Fluoroquinolones (e.g., levofloxacin) if susceptible—successful meningitis/pneumonia/bacteremia cases reported and good CNS penetration for meningitis 5.
       • Trimethoprim-sulfamethoxazole and/or minocycline-based regimens—frequently active and used in severe disease and outbreaks 8, 9.
       • Consider newer fluorocyclines (eravacycline/omadacycline) where available and if susceptibility supports—strong in vitro/in vivo activity against E. anophelis; clinical data emerging 10.
     • Tailor to local susceptibility if available; obtain ID consultation.
   • For meningitis suspicion: prioritize agents with CNS penetration (e.g., levofloxacin, TMP-SMX; minocycline may be adjunct depending on local data) 5, 4.

4. Infection control

   • If in NICU or device-associated settings, reinforce equipment and water-source hygiene; Elizabethkingia outbreaks link to moist environments and milk handling equipment; sterilize feeding/collection gear; this reduces transmission and downstream morbidity/mortality 9.

Pitfalls to avoid

• Acting on a non-quantified, “0 copies” molecular hit—below LOB/LOQ—without confirmation (common cause of overtreatment) 2.
• Relying on phenotype-only identification—E. anophelis is often miscalled as E. meningoseptica; request accurate speciation when positive 8, 3.
• Using carbapenems or broad beta-lactams expecting coverage—intrinsic resistance is common, risking treatment failure 6.
• Ignoring specimen source: low-level reads from non-sterile sites often reflect colonization or environmental DNA, not invasive disease 1.

Exactly what to do next for this patient

• No immediate Elizabethkingia-targeted antibiotics.
• If patient is clinically ill (fever, sepsis, meningitis signs, progressive pneumonia) or the original specimen was blood/CSF:
  • Draw two sets of blood cultures now; obtain CSF studies if meningitis suspected.
  • Request repeat/orthogonal molecular testing with copy number/VAF and QC metrics; ask lab to state LOB/LOD and whether the prior signal exceeded them 2.
• If any confirmatory sterile-site test is positive or a quantitative molecular signal surpasses LOD with compatible syndrome, initiate levofloxacin or TMP-SMX ± minocycline promptly while awaiting susceptibilities; consider eravacycline/omadacycline in MDR settings per local access and ID input 5, 8, 10.